The long-term outcome of chronic epilepsy remains largely unknown, despite a long historical experience. We report the lifelong course of epilepsy of an historical cohort of 235 subjects who were in residential care at the Chalfont Centre for Epilepsy: 122 had comprehensive post-mortem examination. The populations admitted as resident to the centre over time followed the evolution of society's perception of epilepsy. 'Early residents' (before 1972) were admitted for sheltered employment, escaping stigmatization, whereas 'later' residents with more severe epilepsies were admitted for care. Subjects admitted before 1972 were similar to subjects followed nowadays as outpatients, whereas patients admitted later with a higher burden of disabilities are often those in residential care. This long follow-up allowed exploration of a wide spectrum of epilepsies, affecting both subjects who were otherwise healthy and those with co-morbidities. Age at death showed a bimodal distribution with an early peak of mortality between 45-50 years old, whilst the remainder had life expectancy comparable to the general population. As a group, subjects who had post-mortem examination were not significantly different from patients who did not have post-mortem examination, but post-mortem examination provided data that were otherwise unavailable. For those who had post-mortem examination, sudden unexpected death in epilepsy (SUDEP, 18% of all deaths) did not fully explain the early mortality, to which co-morbidities contributed. High seizure frequency was a significant independent predictor of early death even after excluding SUDEP (e.g. reduction in years of life for those who had 44 seizures/month compared with those who had 51 seizure/month: 13 years; 95% confidence interval: 6-19; overall P = 0.0006). Those who survived to older age increasingly went into spontaneous remission lasting until death (in the whole cohort, 38/166, 23% of those who died in or after sixth decade). In subjects who had post-mortem examination, older age (odds ratio = 1.13; 95% confidence interval: 1.06-1.20) and presence of neuropathologically confirmed degenerative changes (that were not the cause of epilepsy) (odds ratio 7.14; 1.95-26.2) were independent predictors of terminal remission. Epilepsy may cause premature death indirectly through co-morbid conditions. Terminal remission occurs even without prior remissions; ageing may improve epilepsy drug responsiveness although unknown factors related to the natural history may also play a role.
Introduction
Chronic epilepsy affects up to a third of subjects with epilepsy but accounts for most of its overall burden (Jacoby et al., 1998) . Numerous treatment approaches (Shorvon, 2009a, b) have been employed to tackle this problem throughout history, accompanied by different social attitudes (Barclay, 1992) . Despite this extensive historical experience, little is known about the long-term outcome of chronic epilepsy and the effect of ageing on active epilepsy. In this historical context, post-mortem examination, despite being decreasingly undertaken (Roberts, 1978) , can provide an assessment of structural abnormalities associated with epilepsy and cause of death, for which MRI cannot act as a complete surrogate. Previous post-mortem studies, however, have been either small or lacking clinical correlations (Corsellis, 1957; Margerison and Corsellis, 1966; Meencke and Janz, 1984) .
Chronic epilepsy is considered a lifelong condition, even if periods of remission occur (Luciano and Shorvon, 2007; Callaghan et al., 2011; Neligan et al., 2011b) . It has also been shown to shorten life expectancy, mostly early after onset (Gaitatzis et al., 2004b) , but also in the long-term (Neligan et al., 2011a) . Causes of death have, however, rarely been investigated with postmortem examination. Heterogeneity of epilepsy is barely considered, prognosis of specific syndromes (important predictors of resistance to treatment) (Semah et al., 1998; Stephen et al., 2001) is largely unknown and neuropathology rarely available. Despite secular changes and changing populations, historical cohorts with lifelong observation in conjunction with post-mortem examination can provide new insights into the long-term outcome of chronic epilepsy.
The Epilepsy Society (www.epilepsysociety.org.uk) administers the Chalfont Centre for Epilepsy. The centre was established in 1892 to provide care, accommodation and employment for people with epilepsy . It was initially intended to be self-sustaining through the work of residents; only subjects capable of working were admitted. In October 1972, the admission policy moved towards care of patients with epilepsy and additional needs (medical or social) (Barclay, 1992) . We present lifelong follow-up of residents who died between 1989 and 2009; postmortem data were available for half. This cohort witnessed the evolution of social and medical management of epilepsy and thus society's perception of people with epilepsy over the past century. This cohort, although inevitably selected, also provides a unique insight into long-term outcome for subjects with chronic epilepsy in terms of life expectancy, causes of death and evolution of seizures over a lifetime, correlated with brain and body pathology.
Materials and methods
The study was approved by the institutional Ethics Committee. All individuals who had post-mortem examination had era-appropriate consent for post-mortem examination and retention of tissue for research; next-of-kin or legal guardian consent was obtained. Relatives or next-of-kin were asked for permission for post-mortem examination for every person dying in this period, unless there were important social considerations.
We collected data of all residents who died between 1989 (when systematic efforts to obtain post-mortem started) and 2009 and studied their life-long evolution. As the post-mortem subgroup had the most complete overall data set (including brain examination), we used all data of those who had post-mortem to analyse predictors of outcome.
Clinical data
Institutional policies ensured comprehensive daily seizure recording (Fig. 1) . Average seizure frequency was arbitrarily categorized yearly as 44 seizures/month, 1-4 seizures/month, or 51 seizure/month. Remission was defined as at least 2 years seizure-free. Medical records were reviewed critically; seizure and syndrome classification was based on clinical description, EEG, neuroimaging, and additional relevant investigations according to the latest International League Against Epilepsy (ILAE) systems (Engel, 2001; Berg et al., 2010) . Residents with cognitive decline in whom dementia was suspected had neuropsychometric assessment. Subjects with longstanding severe intellectual disability without terminal cognitive decline were not considered as having dementia.
Pathology
Formalin-fixed post-mortem whole brains were sliced coronally along the antero-posterior axis. Each slice was examined for macroscopic abnormalities. Systematic histological examination used 5 mm thick blocks taken from the following regions where possible: frontal, parietal, temporal and occipital cortex, insula, cingulum, cerebellum, hippocampus, amygdala, thalamus, basal ganglia, midbrain, pons, medulla and cervical spinal cord. Brains removed at post-mortem were immediately fixed in 10% formalin and suspended. Formalin was changed after 24 h and brains were then fixed for a minimum period of two more weeks. Following fixation, coronal slices were examined at 5-10 mm intervals. In addition to histological sampling of any identified macroscopic abnormality, or presumed electroclinical focus for the onset of seizures, a standard sampling protocol was used, sampling tissue blocks of the hippocampus (usually at two coronal levels), amygdala, superior temporal gyrus, parahippocampal gyrus, anterior frontal (F1/F2), fronto-basal, cingulate, parietal and calcarine cortex. In addition the basal ganglia, thalamus, cerebellum, brainstem and spinal cord, from both left and right sides available, were examined. Tissue blocks were routinely processed, and embedded in Figure 1 An early seizure chart of an individual admitted on 25 May 1926 and started on bromide on his admission; phenobarbital was added to his regimen on 5 June. The white pennant represents daytime, the dark pennant, night-time. Each seizure was recorded with a mark ('x' or '/' or '.') according to severity. Note that seizure classifications varied over the years.
paraffin. In all cases, 5 mm sections were stained with haemotoxylin and eosin and, in the majority of blocks, with additional Luxol Fast blue/cresyl violet. The immunohistochemistry selected for each case varied according to the underlying pathology, but most commonly used markers included antibodies against glial fibrillary acidic protein (GFAP; 1:1500, polyclonal; Dako), CD68 (1:100, monoclonal; Dako; heat pretreatment), neurofilaments [both 1:500; Sternberger Monoclonals (SMI32&31)], dynorphin (1:100; AbD Serotec) and phosphorylated tau protein (1:1200, monoclonal antibody AT8; Innogenetics, Autogen Bioclear), on 8-14 mm sections.
The qualitative assessment of hippocampal sclerosis at post-mortem has been previously validated in a stereological study (Thom et al., 2005) . Dynorphin immunohistochemistry for confirmation of epilepsyspecific mossy fibre sprouting was carried out in the majority of cases with hippocampal sclerosis (Thom et al., 2009) . Pathological evidence of old traumatic brain injury, for example old cortical contusions or subdural haematoma, was recorded based on macroscopic and histological sections. The presence of cerebrovascular disease of all types (degenerative small vessel white matter disease, regional cortical infarction, and spontaneous cerebral haemorrhage or lacunar infarcts) was noted. The presence of atheroma in the main cerebral vessels alone was not regarded as sufficient for a diagnosis of cerebrovascular disease. In cases with suspected neurodegenerative diseases, appropriate immunohistochemistry for abnormal neuronal inclusions and protein accumulation, including ubiquitin, phosphorylated tau protein, alpha-synuclein and bA4 amyloid staining, was carried out.
We also integrated pathological data from previous studies [for hippocampal sclerosis (Thom et al., 2009) , and Dravet syndrome ] and used the same unified subject numbering system, allowing correlation of different aspects across publications (Thom et al., 2005 Liu et al., 2012; Martinian et al., 2012) . A brain structural abnormality (including stroke or traumatic lesions) seen at post-mortem was considered the presumed cause of epilepsy if in keeping with clinical and paraclinical data. Macroscopic body postmortem examination was performed and abnormalities were further studied histologically. Sudden unexpected death in epilepsy (SUDEP) was defined as death in which no cause was found at autopsy (i.e. requiring post-mortem examination), occurring in benign conditions, without evidence of status epilepticus or traumatic event (Nashef et al., 2012) .
Statistics
Chi-squared, Fisher's exact, Kruskal-Wallis and Mann-Whitney tests were used as appropriate in univariate analyses. Multivariate regression analyses of age at death (i.e. length of life) were performed using a backward-stepwise approach first entering all factors that had P 4 0.1 in univariate analyses. The assumptions of multiple regression (normally-distributed residuals) were checked. Logistic regression analysis using a similar modelling strategy was used to investigate factors associated with the binary outcome, terminal remission. Analyses were conducted using SPSS version 20 (SPSS Inc.) or Stata (v10; Statacorp Inc.) .
Results

Demographic and clinical data
Between 1989 and 2009, 235 residents died; 122 (52%) had postmortem examination, all with brain autopsy (10 had no microscopic examination); in seven, autopsy was limited to the brain. Comparison of characteristics of subjects who had postmortem examination with those who did not showed no significant differences for gender, age at death, epilepsy duration, age at admission, year of admission, length of residence, number of antiepileptic drugs tried, proportion of generalized versus focal epilepsy, episodes of status epilepticus, learning disabilities, transient episodes of remission, or terminal remission. Although there was marked variability in the distribution of seizure frequency category between subjects who had a post-mortem examination and those who did not (51 seizure per month: 35% versus 13%, 1-4 seizures per months: 34% versus 61%, 44 seizures per month: 31% versus 25%, P 5 0.0001), there was no linear trend (P = 0.395); the differences are not meaningful. Detailed demographic, clinical and pathological data of subjects who had post-mortem examination are given in Table 1 .
Fifty-two subjects (43%) were admitted after October 1972 (admission policy change date); they were older on admission, had more frequent seizures and more frequently had intellectual disability, multiple seizures types (54), a genetic cause, generalized epilepsy and degenerative disease (Table 1) .
In subjects having post-mortem examination, 45 had an MRI brain scan, and 43 had a CT scan; 14 had both. Median year of MRI scan was 1997 (range 1990-2001) . MRI scanning (1.5 T) was set up at the Chalfont Centre in late 1995. The proportion of subjects who had MRI was mostly a matter of availability; most subjects who died after 1995 had had a pre-mortem MRI scan (42/69, 61%), whereas subjects who died in 1995 or earlier rarely had an MRI scan (3/53, 6%, P 5 0.0001). Subjects admitted before 1972 tried fewer antiepileptic drugs (fewer were available). With one exception, all subjects were treated at some point with at least one enzyme-inducing anti-epileptic drug.
Two subjects had underlying genetic causes confirmed (one Unverricht-Lundborg disease, one Dravet syndrome). Six had a clinically-suspected genetic cause for their epilepsy: Dravet syndrome was suspected in two, dentatorubral-pallidoluysian atrophy in two, familial Alzheimer's disease (with Alzheimer pathology) in one and neuroacanthocytosis in one. Fourteen other subjects had potential genetic causes for epilepsy based on presence of additional somatic malformations, family history, bilateral cortical malformation or facial dysmorphism.
Pathology
Causes of death are detailed in Table 1 for subjects who had postmortem examination. Thirty-five patients (29%) died suddenly, but 14 of these-who might otherwise have had a diagnosis of SUDEP-were shown at post-mortem to have probable cardiovascular causes of death. Subjects admitted before October 1972 died less frequently of SUDEP and more frequently of pneumonia (both diagnosed at post-mortem examination). A structural abnormality presumably accounting for epilepsy was found in 86 subjects (70%). Of the 45 subjects that had MRI scans, 14 had no relevant abnormality at post-mortem examination; only one was found to have a structural abnormality (hippocampal sclerosis) at MRI scan not confirmed at post-mortem examination (post-mortem examination results were considered as reference). Of those who had structural abnormalities at post-mortem examination (n = 32), the abnormalities were not seen on pre-mortem MRI in 14 (45%). Structural abnormalities found on neuropathology and not seen on pre-mortem brain MRI were hippocampal sclerosis (10; 71%), cortical malformation (3; 21%) and one degenerative condition (7%). Hippocampal sclerosis was the most common pathology considered capable of causing seizures (45% of all cases); 30 cases with hippocampal sclerosis had a clinical picture compatible with mesial temporal lobe epilepsy. Structural abnormalities are detailed in Table 1 . Three had post-mortem findings suggesting an unsuspected genetic cause: tuberous sclerosis in two, and neurodegeneration with brain iron accumulation type 1 in one. The following pathologies were labelled degenerative, irrespective of whether they were considered the cause of the epilepsy or not: neuritic plaques and/or neurofibrillary tangles (sometimes in the Alzheimer's disease spectrum), found in 26 subjects; tauopathies, found in two subjects; ubiquitin inclusions, found in one subject; intranuclear hyaline inclusions (one subject) and Lewy bodies (mainly brainstem, one subject). These changes were noted only on post-mortem and would not have been visible on MRI. One or more lesions not presumed to be the cause of epilepsy were found in 68 subjects (56%); 20 (29%) had traumatic lesions, 45 (66%) ischaemic lesions, and 31 (45%) degenerative lesions.
Seizure evolution and remission
In the whole cohort (n = 235), median duration of residential care was 29 years (range: 2 months to 72 years). During follow-up, most subjects (175/235, 74%) had lifelong seizures with overall stable seizure frequency (no switching between seizure-frequency categories). Thirty-five (15%) experienced at least one period of relapsing remission [median: one remission (range: 1-3), median remission length for all remissions: 4 years (range: 2-28 years)]. Thirty-nine (17%) went into remission without further relapse until death ('terminal' remission). Median duration of terminal remission was 6 years (range 2-41 years) with median age of terminal remission onset of 67 (33-92 years). Most subjects (25/39, 64%) in terminal remission at death had no previous remission. The proportion of subjects in terminal remission increased with age (Fig. 2) .
Among subjects who had post-mortem examination, established already as representative of the whole cohort, 26 (21%) entered terminal remission; of those (22/26, 85%) had their last medication change more than a year (median 5 years) before onset of terminal remission. For subjects with earlier relapsing remissions, most drug changes occurred significantly closer to the remission [within a year in 52%; P = 0.005 (36% within 6 months)]. The eight subjects in terminal remission with previous remissions were not significantly different from those with earlier remission periods but no terminal remission, in terms of the number of earlier periods of remission (median 1 versus 2 years, P = 0.17), longest earlier remission (median 3 versus 5 years, P = 0.2) and total time in earlier remission (median 8 versus 6 years, P = 0.81). Univariate and multivariate predictors of terminal remission in subjects with post-mortem examination are shown in Table 2 . In subjects admitted before October 1972, older age at death and The cohort is divided into subjects who were admitted before October 1972 (date of change of admission policy) or after. For seven subjects (6%), epilepsy syndrome was unclassified. All typical/atypical absences were electrophysiologically proven. Fourteen people who died of sudden death (14/35, 40%) and might have been considered as SUDEP were shown to have cardiovascular cause of death at post-mortem examination.
*Data for somatic condition and physical disabilities at admission were available for 92 subjects. **Genetic cause diagnosed clinically, genetically confirmed or diagnosed at post-mortem examination. ***Potential genetic cause is based on presence of somatic malformations, family history, bilateral cortical malformation, and/or facial dysmorphism. † Cortical malformation included: focal cortical dysplasia (n = 10), periventricular heterotopia (n = 6), polymicrogyria (n = 5), band heterotopia (n = 4), tubers (n = 2); three people had two distinct types of malformation.
z Assessed before admission and over the first year of residency.
degenerative changes not thought to be the cause of epilepsy were independent predictors of terminal remission (data not shown). Only three subjects admitted after 1972 went into terminal remission (predictors in the whole cohort can be found in Supplementary material). In two subjects who had no previous period of remission and who went into spontaneous terminal remission, post-mortem examination showed lacunar infarctions in periventricular heterotopia (Fig. 3) . Degenerative changes thought not to be the cause of epilepsy were not associated with clinical dementia (26%, P = 0.39).
Mortality
Age at death in the whole cohort showed a bimodal distribution with a first peak $45-50 years (early mortality in comparison with the general population) and a second at 70-85 years (Fig. 4) . Among subjects who had post-mortem examination, those admitted after October 1972 died younger (Table 1) . Death as a direct consequence of seizures was rare (gastric aspiration in two and traumatic intracranial haemorrhage in one). SUDEP, more frequent in subjects dying aged 563 years (the median age of death), did not entirely explain early mortality (Fig. 1) . Age of death was similar for those who died of cardiovascular causes (n = 40), respiratory causes (n = 40) and other causes excluding epilepsy-related deaths (n = 18; P = 0.26). Univariate and multivariate predictors of age at death are shown in Table 2 for the cohort with post-mortem and for subjects with post-mortem who died from causes other than SUDEP or seizure-related death. Genetic cause had the strongest effect with an adjusted mean difference in length of life of 21 years (Table 2) . Pathologically diagnosed underlying causes were not independent predictors of early mortality. Presence of comorbidity at admission did not predict age of death. Higher seizure frequency was an independent predictor of earlier age of death for subjects admitted before or after 1972 analysed as separate groups (predictors in the whole cohort can be found in Supplementary material). Considering all individuals with potential underlying genetic conditions, genetic cause still represented the strongest predictor of age at death when excluding SUDEP and seizure-related deaths (data not shown). Higher seizure frequency was associated with earlier death with adjusted mean difference of 18 years between those with 51 and 44 seizures/month, including all deaths (Table 2 ).
Discussion
The Chalfont Centre was founded during an era when the position of subjects with epilepsy in society was particularly difficult (Barclay, 1992; Sander et al., 1993; Duncan and Faulkner, 2003; Shorvon, 2011) . In late Victorian industrialized society, people with epilepsy struggled immensely to find employment and housing due to stigma associated with the condition. They often ended up in workhouses or psychiatric asylums. It became increasingly recognized by philanthropists and physicians treating epilepsy that another solution had to be found particularly for so-called 'sane epileptics' (Lannon, 2002) . Eugenicist ideas were also widely embraced (Llewellyn, 1998) ; it was feared that 'unfit' subjects (including those with epilepsy) (Norrgard, 2008) were having the largest families because of indiscriminate charity work that could endanger the survival of the 'fittest' individuals. Establishing an isolated, self-financing, agricultural 'colony' away from the hustle and bustle of the cities where people with epilepsy could work, providing them with 'healthy occupation' seemed the ideal Victorian solution. From a research perspective it could be speculated that it was felt that the 'colony' was likely to provide valuable insights into epilepsy, with a cohort that could be closely followed and investigated . In 1892, a college of consultants from the National Hospital for the Paralysed and Epileptics in Queen Square, London together with the Lady Samaritans Society of the hospital founded the National Society for Employment of Epileptics (NSEE). It was soon established in the countryside west of London near Chalfont-St-Peter. The 'colony' progressively grew, hosting subjects employed in various occupations such as tailors, farmers, carpenters, ironworkers or brickmakers. The number of 'colonists' reached 524 in the early 1950s. With improving understanding and treatment of epilepsy, institutions hosting residents were increasingly felt to be old-fashioned and segregational as highlighted in the Reid report (1969) . The colony began a conversion into a centre specializing in the assessment of subjects with epilepsy. From 1972 onward, longterm admission policies changed towards residential care of subjects having epilepsy associated with other conditions. Admission of patients with epilepsy having either another medical condition, Figure 2 Proportion of subjects in terminal remission according to their age at death in the whole cohort (235 subjects). Light grey columns represent subjects that continued to experience seizures until their death and dark grey columns represent subjects in final remission at their death; scale on left is number of subjects. Darkest grey columns represent subjects who went into terminal remission and had post-mortem examination. The black dotted line represents the percentage of subjects in terminal remission at each decade (not cumulative) (scale on the right).
or intellectually or physically disabled, was favoured. A rehabilitation unit was set up, allowing comprehensive assessment (medical and social) of subjects with epilepsy during shorter stays.
Our cohort witnesses this evolution; it consists of two populations nowadays encountered in different settings; subjects who would probably be independent in the community (admitted for employment, 57%) and subjects needing institutional care or supported living (admitted for care). Subjects admitted before October 1972 (before admission policy changes) had milder epilepsy and the proportion with intellectual disabilities was closer to that in subjects with epilepsy living independently nowadays (Hitiris et al., 2007) . The frequency of remissions was very similar to that reported in outpatients of tertiary centre settings currently (Neligan et al., 2011b) , as was the proportion with symptomatic (structural/metabolic) epilepsy [69% in our cohort versus 65-71% (Semah et al., 1998; Stephen et al., 2001) ], and the distribution of presumed causes (Semah et al., 1998; Stephen et al., 2001) . Some underlying abnormalities (such as cortical malformations) were more frequent in our post-mortem cohort than in imaging-based studies (Semah et al., 1998; Stephen et al., 2001) . Subjects admitted later had more severe epilepsy, more genetic disease, some had degenerative disease and the proportion with intellectual disability was close to that in subjects in other institutions (Iivanainen and Lehtinen, 1979) . The heterogeneity of our cohort allows exploration of long-term outcome in a wide spectrum of epilepsies. All individuals in our cohort had, at some point, drug-resistant epilepsy according to the definition of the ILAE (Kwan et al., 2010) , but would be better described as having chronic epilepsy, as a third had prolonged periods of remission. Mortality at the centre is closely monitored and reviewed; there was no secular change between 1896 and 1990 despite treatment evolution (Klenerman et al., 1993 ; O'Donoghue and Sander, 1997). In the two contrasting populations investigated here ('early' versus 'later' residents), the same findings of early mortality or terminal remission emerged, suggesting that the predictors found in this study are not specific only to a highly-selected population with severe epilepsy (i.e. the 'later' residents). In this context, we note that the overall prognosis of chronic epilepsy has not dramatically changed in recent years; new anti-epileptic drugs have not significantly increased the proportion of subjects in remission (Stephen et al., 2012) and only a minority of patients with drug-resistant epilepsy are suitable for curative surgery (Engel et al., 2008) . The lifelong follow-up of this large cohort of subjects with chronic epilepsy showed a biphasic evolution of epilepsy. There was a peak of premature mortality at $45-50 years, followed by an increasing likelihood of terminal remission in those who survived this first peak of mortality. Terminal remissions were not associated with a previous pattern of remission and relapse. In contrast to previous relapsing remissions, terminal remissions were not linked in time with changes of medication. They were associated only with older age and degenerative changes (that were not the cause of the epilepsy) seen at post-mortem. Higher seizure frequency was associated with younger age at death (remotely from epilepsy onset) even when definite SUDEP (i.e. confirmed by negative post-mortem examination) as a cause of death was formally excluded; the highest seizure frequency shortened life on average by 18 years. Previous reports showing a peak of mortality between 10 and 20 years after epilepsy onset (Hauser et al., 1980; Lindsten et al., 2000; Lhatoo et al., 2001; Camfield et al., 2002) did not have post-mortem data for a formal diagnosis of definite SUDEP.
Subjects with post-mortem examination were not significantly different from others; the main findings were similar to those from the whole cohort, but more complete data were available in subjects with post-mortem examination. Post-mortem examination also allowed a detailed determination of risk factors for epilepsy and cause of death. Judged against post-mortem examination, MRI brain scanning (at 1.5 T) had a relatively low rate of false positivity of 7%, but the rate of false negativity rose to 45%. Among 11 subjects with an underlying genetic condition, three (27%) were only identified at post-mortem examination, without any pre-mortem indication of the diagnosis. In sudden death cases that would have been diagnosed clinically as probable SUDEP (Nashef et al., 2012) , post-mortem examination revealed a different cause of death (cardiovascular) in 40% of cases. Post-mortem examination also allowed sensitive identification of degenerative changes that were not apparent clinically, for example they may not have been accompanied by cognitive decline (in 74% of cases). Post-mortem examination therefore provided a sensitive Long-term outcome of chronic epilepsy and valuable complement to clinical data in terms of epilepsy causes, occurrence of secondary lesions, and causes of death, and adds important information to our analysis.
Mortality
We found a bimodal distribution of age at death. Early mortality in the community is mostly related to the underlying presumed cause of epilepsy (Neligan et al., 2010) ; this was not the explanation here as subjects with sinister underlying conditions were not admitted as long-term residents for employment (Fig. 5) . SUDEP is a major contributor to the early mortality of chronic epilepsy (Nashef et al., 1995) , and it was the second most common cause of death. Post-mortem confirmed (i.e. definite) SUDEP was only responsible for some of the early deaths, suggesting that epilepsy can also lead to premature death through other mechanisms.
Those who died of causes other than SUDEP or directly from epilepsy-related deaths had similar age of death for cardiovascular, respiratory or other causes, suggesting that no single cause was responsible for earlier deaths; this accords with reports showing that long-term excess mortality rates are seemingly not directly related to the disease (Neligan et al., 2011a) . Disease severity (as measured by seizure frequency) was a major predictor of age of death in non-epilepsy related deaths as diagnosed at post-mortem, suggesting that co-morbidities (or their consequences) may be linked with epilepsy severity. Furthermore, the effect of disease severity seems not to be due to the presence of somatic co-morbidities present early in the course of the disease, as higher prevalence of somatic co-morbidities at admission was not a predictor of age at death. Treatment seems not to be an obvious bias; there was no disparity in terms of exposure to enzyme-inducing anti-epileptic drugs (shown to increase the risk for cardiovascular disease) (Mintzer et al., 2009) , although subjects with more severe epilepsy were exposed to a higher number of different treatments. The higher burden of somatic co-morbidity in subjects with epilepsy (Gaitatzis et al., 2004a (Gaitatzis et al., , 2012 TellezZenteno et al., 2005) could conceivably be worsened by more severe disease. A common genetic predisposition to epilepsy and co-morbid conditions may also be postulated (Kasperaviciute et al., 2011) , as an underlying genetic causation was a major predictor of early death (Table 2) .
Our results suggest that drug changes might decrease the early mortality by reducing the seizure frequency, supporting the view that a reduction of seizure frequency is worthwhile even when seizure-freedom cannot be achieved (Kwan et al., 2010) . Our findings also suggest that the general health of subjects with severe epilepsy needs careful attention.
Remission
The disease burden (in term of seizures) appeared to decline as increasing numbers of subjects went into terminal remission with ageing, among those who survived, who generally had less severe epilepsy. Transient periods of remission are well described in drugresistant epilepsy, usually, though not exclusively (Callaghan et al., 2007; Wang et al., 2013) , linked to treatment changes (Luciano and Shorvon, 2007; Callaghan et al., 2011; Neligan et al., 2011b) . Terminal remission in our cohort seemed to be a distinct phenomenon, not being directly related to treatment changes and not preceded by previous remission in most subjects. Terminal remissions were all of sufficient length as to be considered not just due to chance, adapting a recently suggested rule for use after interventions (Brandon Westover et al., 2012) . Seemingly spontaneous remissions have been reported in elderly subjects who had previously had lifelong intractable seizures (Cockerell et al., 1995) , designated at the time as 'burned-out' epilepsies. Although terminal remissions appeared not to be directly triggered by treatment change, a previous study from our institution showed that withdrawing anti-epileptic drugs frequently led to relapse (Koepp et al., 2008) , suggesting that perhaps the epilepsy became drugsensitive, in line with evidence showing that response to medication increases with ageing (Stephen et al., 2006) .
Terminal remission seemed partly related to ageing, as older age, and degenerative changes (that were not the cause of epilepsy) determined at post-mortem examination (and possibly occurring after the onset of epilepsy), were independent predictors. These findings are compatible with epidemiological evidence of a prevalence of epilepsy in the elderly that is the same as in the general population despite a significantly increased incidence (Faught et al., 2012) , suggesting that elderly subjects with epilepsy have either an increased early mortality or a higher proportion of terminal remission (resolution) (Berg, 2012) . Ageing (such as neuronal loss or dysfunction, degenerative changes) may affect the epileptogenic tissue, possibly decreasing the burden of epileptogenic neurons (Sen et al., 2007) . Ageing was also shown to be a protective factor against epilepsy in subjects with Alzheimer's disease, as the risk of developing epilepsy decreased with increasing age in Alzheimer's disease (Amatniek Figure 5 Chalfont residents at work (circa 1920-1940) . The photographs, courtesy of the Epilepsy Society, show that residents admitted before 1972 were typically otherwise healthy young subjects and were employed in efforts such as harvesting. et al., 2006) . Degenerative changes (that were not the cause of epilepsy) had a synergistic effect with ageing. The range of diagnoses for the degenerative changes was wide. We chose not to use Braak staging to stratify degenerative changes as tau protein accumulation in epilepsy is not exclusively related to Alzheimer's disease, but also seen for example with traumatic brain injuries . Two individuals who went into spontaneous remission were found to have lacunar infarctions in the presumed epileptogenic tissue. This may have been relevant to the occurrence of spontaneous remission, but the very small number of cases does not allow us to conclude that lacunar infarctions contribute more generally to spontaneous remission outside these particular cases. Subjects with hippocampal sclerosis were less likely to have terminal remission. Whether this relates to hippocampal sclerosis specifically, or more widely to 'hippocampal' rather than neocortical epilepsy, is unclear. Animal studies show that the hippocampus continues to generate new neurons in adulthood (Kempermann et al., 2000) , a process enhanced by seizures (Parent et al., 1997) , possibly counterbalancing the loss of epileptogenic neurons occurring with age. Degenerative changes may also increase the overall excitability of hippocampal circuitry (Noebels, 2011) . The next step would be to compare in detail the brain pathology of subjects in this cohort who died after lifelong seizures with those who died at comparable ages, but in terminal remission. This could identify new pathways or potential targets in the treatment of drug-resistant epilepsy.
This study is limited by its selected, heterogeneous and retrospective nature. Only subjects who died whilst residents at the Chalfont Centre for Epilepsy were included, and thus not considered were subjects discharged (having probably improved during their stay), potentially overestimating the importance of the identified early peak of mortality, but also possibly underestimating the proportion of subjects entering terminal remission later. The two contrasting populations differed by institutional admission criteria over the two distinct historical periods, and cannot therefore be used to provide insight into temporal changes in epilepsy over the whole duration of the study. Because of secular changes in seizure nomenclature and descriptions, it was not possible to assess the importance (e.g. proportion) of individual seizure types, known to be an important factor in SUDEP (Nashef et al., 1995) . Historical data also did not allow the use of current criteria in terms of syndromic diagnosis, whilst for example video telemetry and multimodal imaging could now determine more reliably the relation between cerebral lesion and seizures. The available MRI data also would not today be considered state-of-the-art.
Despite being selected, this historical cohort provides valuable insights into the long-term outcome of epilepsy. Epilepsy severity appears to be a major factor influencing life expectancy of subjects with chronic epilepsy even when excluding epilepsy-related deaths. With ageing, the disease tended to improve, possibly becoming drug-responsive .
